April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
The Effectiveness of Infliximab for Refractory Uveitis Due to Behcet’S Disease
Author Affiliations & Notes
  • T. Ito
    Ophthalmology, Kyushu University, Fukuoka, Japan
  • K. Hijioka
    Ophthalmology, Kyushu University, Fukuoka, Japan
  • T. Fujimoto
    Ophthalmology, Kyushu University, Fukuoka, Japan
  • K.-H. Sonoda
    Ophthalmology, Kyushu University, Fukuoka, Japan
  • T. Ishibashi
    Ophthalmology, Kyushu University, Fukuoka, Japan
  • Footnotes
    Commercial Relationships  T. Ito, None; K. Hijioka, None; T. Fujimoto, None; K.-H. Sonoda, None; T. Ishibashi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 6026. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Ito, K. Hijioka, T. Fujimoto, K.-H. Sonoda, T. Ishibashi; The Effectiveness of Infliximab for Refractory Uveitis Due to Behcet’S Disease. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6026.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Infliximab is an anti-tumor necrosis factor-alpha (TNF-) antibody, and has been used for the treatment of Crohn disease and rheumatoid arthritis. It is known that serum concentration of TNF- is elevated in patients with Behcet’s disease (BD) . Infliximab is officially approved for the treatment of refractory uveitis due to BD in Japan since January 2007. We herein report the effectiveness of Infliximab against ocular BD.

Methods: : Retrospective evaluation of 18 BD patients with refractory uveitis despite under the treatment of colchicine and/or cyclosporine at Kyushu University. They were treated by Infliximab at a dose of 5mg/kg in a single intravenous infusinon on zero, two weeks, six weeks, and every eight weeks. Patients were all male and the mean age was 40.7 years old. The main outcome measures were the number of uveitis attack, visual acuity, and systemic side effects.

Results: : The mean follow-up period was 15 months (range: 2-25 months). In all patients, the frequency and seriousness of uveitis attack was decreased remarkably, and in four patients, uveitis attack was not caused at all. The extra-ocular symptoms were also improved. So far, we have not observed systemic severe side effects.

Conclusions: : Infliximab is effective and safe for refractory uveitis due to BD. We need to pay attention to side effects for the longer time.

Keywords: retina • uvea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×